Correlation of Moxifloxacin Concentration, C-Reactive Protein, and Inflammatory Cytokines on QTc Interval in Rifampicin-Resistant Tuberculosis Patients Treated with Shorter Regimens
Keywords:
pulmonology, tropical disease, infectionAbstract
Background: Drug-resistant tuberculosis (DR-TB) is a global health concern. QTc prolongation is a serious adverse effect in DR-TB patients receiving a shorter regimen. This study aimed to evaluate the correlation of moxifloxacin concentration, CRP, and inflammatory cytokines with QTc interval in DR-TB patients treated with a shorter regimen. Methods: This study was performed in 2 groups of rifampicin-resistant (RR-TB) patients receiving shorter regimens. Correlation for all variables was analyzed. Results: CRP, IL-1β, and QTc baseline showed significant differences between 45 RR-TB patients on intensive phase and continuation phase with p-value of <0.001, 0.040, and <0.001, respectively. TNF-α and IL-6 between RR-TB patients on intensive phase and continuation phase showed no significant difference with p=0.530 and 0.477, respectively. CRP, TNF-α, IL-1 β, and IL-6 did not correlate with QTc interval in intensive phase (p=0.226, 0.281, 0.509, and 0.886, respectively), and also in continuation phase (0.805, 0.865, 0.406, 0.586, respectively). At 2 hours after taking the 48th-dose, moxifloxacin concentration did not correlate with QTc interval, both in intensive phase (p=0.576) and in continuation phase (p=0.691). At 1 hour before taking the 72nd-hour dose, moxifloxacin concentration also did not correlate with QTc interval in intensive phase (p=0.531) and continuation phase (p=0.209). Conclusion: Moxifloxacin concentration, CRP, and inflammatory cytokines did not correlate with QTc interval in RR-TB patients treated with shorter regimens. The use of moxifloxacin is safe but should be routinely monitored and considered the presence of other risk factors for QTc prolongation in RR-TB patients who received shorter regimens.References
World Health Organization. Global Tuberculosis Report. Geneva: World Health Organization; 2020.
World Health Organization. WHO Treatment Guidelines for Drug-Resistant Tuberculosis: 2016 Update. Geneva: World Health Organization; 2016.
Indonesian Ministry of Health. Technical Guideline for Drug-Resistant Tuberculosis Treatment with Shorter Regimens in Health Care Facility. Jakarta: Indonesian Ministry of Health; 2017.
Soedarsono S, Kusmiati T, Wulaningrum PA, et al. Factors Cause of Switching Shorter Regimen to Longer Regimen in Multidrug-Resistant/ Rifampicin-Resistant Tuberculosis Treated Patients in Dr. Soetomo Hospital Surabaya, Indonesia. Indian J Med Forensic Med Toxicol 2021; 15: 1589-1595.
Kusmiati T, Mertaniasih NM, Putranto JN, et al. Factors that Contribute to the QTc Interval Prolongation in DR-TB Patients on STR Regimen. Indian J Med Forensic Med Toxicol 2020; 15: 1618-1625.
Khan F, Ismail M, Khan Q, Ali Z. Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review. Expert Opin Drug Saf 2018; 17(10). https://doi.org/10.1080/14740338.2018.1520837.
Lazzerini PE, Laghi-Pasini F, Bertolozzi I, Morozzi G, Lorenzini S, Simpatico A, et al. Systemic inflammation as a novel QT-prolonging risk factor in patients with torsades de pointes. Heart (British Cardiac Society) 2017; 103 (22):1821-1829. doi:10.1136/heartjnl-2016-311079.
Lazzerini PE, Capecchi PL, El- Sherif N, Pasini FL, Boutjdir M. Emerging Arrhythmic Risk of Autoimmune and Inflammatory Cardiac Channelopathies. J Am Heart Assoc 2018; 7: e010595. Doi: 10.1161/JAHA.118.010595.
Kim E, Joo S, Kim J, Ahn J, Kim J, et al. Association between C-reactive protein and QTc interval in middle-aged men and women. Eur J Epidemiol 2006; 21(9): 653–659.
Sproston NR, Ashworth. Role of C-Reactive Protein at Sites of Inflammation and Infection. Front Immunol 2018; 9: 754.
Pansey P, Shukla S, Acharya S. Serum C-reactive protien (CRP) - a dependent prognostic marker in pulmonary tuberculosis. International Journal of Contemporary Medical Research 2017;4(10):2111-2114.
Xie Y, Mai JT, Wang F, Lin YQ, Yuan WL, Luo NS, Fang MC, Wang JF, Chen YX. Effects of C-reactive protein on K+ channel interaction protein 2 in cardiomyocytes. Am J Trans Res 2015; 7(5): 922-931.
Yoon HY, Jo KW, Nam GB, Shim TS. Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease. Int J Tuberc Lung Dis 2017; 21(9): 996-1001.
United States Agency for International Development. Guide for QTc monitoring and management of drug-resistant TB patients with QT-prolonging agents. New York: USAID; 2018.
Indonesian Ministry of Health. Technical Guideline for Programmatic Management of Drug Resistant Tuberculosis. Jakarta: Indonesian Ministry of Health; 2014.
Indonesian Ministry of Health. Guidelines for Drug-Resistant Tuberculosis Management in Health Care Facility. Jakarta: Indonesian Ministry of Health; 2019.
Weyer K. Multidrug-Resistant Tuberculosis. CME 2005; 23(2): 74-84.
Brode SK, Varadi R, McNamee J, Malek N, Stewart S, Jamieson FB, et al. Can Respir J 2015; 22(2): 97-102.
Migliori GB, Tiberi S, Zumla A, Petersen E, Chakaya JM, Wejse C, et al. MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis 2020; 92S: S15-S25.
Kusmiati T, Suci YD, Dewi KP, et al. QTc Interval Prolongation in Drug Resistant Tuberculosis Patients Treated with Shorter Treatment Regimens. Med Leg J Update 2021; 21: 1208-1215.
Chang KT, Shu HS, Chu CY, Lee WH, Hsu PC, Du HM, et al. Association between C-reactive protein, corrected QT interval and presence of QT prolongation in hypertensive patients. Kaohsiung Journal of Medical Sciences 2014; 30: 310-5.
Kobayashi H, Kobayashi Y, Yokoe I, Kitamura N, Nishiwaki A, Takei M, et al. Heart rate–corrected QT interval duration in rheumatoid arthritis and its reduction with treatment with the interleukin 6 inhibitor tocilizumab. J Rheumatol 2018;45:1620-7.
Panoulas VF, Toms TE, Douglas KM, Sandoo A, Metsios GS, Kalinoglou AS, et al. Prolonged QTc interval predicts all-cause mortality in patients with rheumatoid arthritis: an association driven by high inflammatory burden. Rheumatology 2014;53:131-7.
Medenwald D., Kors JA, Loppnow H, Thiery J, Kluttig A, Nuding S, et al. Inflammation and Prolonged QT Time: Results from the Cardiovascular Disease, Living and Ageing in Halle (CARLA) Study. PLoS ONE 2014; 9(4):e95994.
Pisoni CN, Reina S, Arakaki D, Eimon A, Carrizo C, Borda E. Elevated IL-1beta levels in anti-Ro/SSA connective tissue diseases patients with prolonged corrected QTc interval. Clin Exp Rheumatol 2015; 33(5): 715–20.
Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109[suppl II]:II-2–II-10.).
Soedarsono S, Subiantoro MC. Changes of CRP serum levels in pulmonary TB patients with AFB smear-positive sputum before and two months after receiving anti-tuberculosis drug treatment. Indian J Tuberc 2019; 66: 134-8.
Romero-Adrian TB, Leal-Montiel J, Fernandez G, Valecillo A. Role of Cytokines and Other Factors Involved in the Mycobacterium tuberculosis Infection. World J Immunol 2015; 5(1): 16-50.
Chandrashekara S. C - reactive protein: An inflammatory marker with specific role in physiology, pathology, and diagnosis. IJRCI 2014; 2(S1): SR3. DOI: 10.15305/ijrci/v2iS1/117.
Aromolaran AS, Srivastava U, Ali A, Chahine M, Lazaro D, El-Sherif N, et al. Interleukin-6 inhibition of hERG underlies risk for acquired long QT in cardiac and systemic inflammation. PloS ONE 2018; 13(12): e0208321. https://doi.org/10.1371/journal.pone.0208321.
Watson KJ, Gorczyca WP, Umland J, et al. Pharmacokinetic–pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys. J Pharmacol Toxicol Methods 2011; 63: 304-313.
Nachimutu S, Assar MD, Schussler JM. Drug-Induced QT Interval Prolongation: Mechanisms and Clinical Management. Ther Adv Drug Saf 2012; 3: 241-253.
Cubeddu, L. Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias. Curr Cardiol Rev 2016; 12: 141-154.
Downloads
Published
How to Cite
Issue
Section
License
Copyright
The authors who publish in this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.